Day 1 | Day 2 | Download Brochure
TUESDAY, JUNE 5
7:15 am Registration & Morning Coffee
8:15 Chairperson’s Opening Remarks
» 8:25 Keynote Presentation
Terry A. Van Dyke, Ph.D., Head, Mouse Cancer Genetics Program; Program Director, Cancer Pathways and Mechanisms, National Cancer Institute
|
9:10 From Cell Lines to Mouse Models: Building Pre-Clinical Oncology Models to Match Targeted Therapies to Cancer Patient Populations
Nancy K. Pryer, Ph.D., Director, Oncology Pharmacology, Novartis Institutes for Biomedical Research
9:40 A Hedgehog-Dependent Barrier to Drug Delivery in Pancreatic Cancer - Translation from Mice to Patients
Kenneth Olive, M.D., Assistant Professor of Medicine and Pathology, Irving Cancer Research Center, Columbia University
10:10 Coffee Break
Sponsored by
10:40 Beyond Cell Lines: Building Confidence in Predictive Markers Using Ex Vivo Drug Treatment Models with Patient Derived Tumor Specimens
Thomas B. Broudy, Ph.D., CSO, Molecular Response
10:55 Sponsored Presentation (Opportunity Available)
11:10 Discovery of Candidate Biomarkers of Anticancer Drug Sensitivity by High-Throughput Cell Line Screening
Cyril H. Benes, Ph.D., Principal Investigator and Director, Center for Molecular Therapeutics, Massachusetts General Hospital Cancer Center
11:40 Assessing Therapeutic Responses in Genetically Engineered Mouse Models of Cancer
Mallika Singh, Ph.D., Scientist, Department of Molecular Biology. Genentech
12:10 pm Luncheon Presentation
Sponsored by
Applications of Global Metabolomics in Drug Discovery
Mike Milburn, Ph.D., CSO, Metabolon, Inc.
1:10 Session Break
1:30 Chairperson’s Remarks
1:40 Future Advances in Oncology Drug Development: Characterization Patient-Derived Explants in Comparison to Standard Human Tumor Cell Line-Derived Xenografts
Robert Wilkinson, Ph.D., Principal Scientist II, Oncology Innovative Medicines (iMED), AstraZeneca UK Limited
2:10 Exploring of Non-Germline Genetically Engineered Mouse Cancer Models for Translational Discovery and Pre-Clinical Drug Development
Serguei Kozlov, Ph.D., Principal Scientist, Center for Advanced Pre-Clinical Research, SAIC-Frederick, Inc.
Sponsored by
2:40 The JAX Patient Derived Xenograft (PDX) Cancer Consortium: Changing the Course of Clinical Advancement
Neal Goodwin, Ph.D., Director, Research and Development, In Vivo Pharmacology Services, The Jackson Laboratory
3:10 Is the Use of Orthotopic Oncology Models a Necessity or a Luxury?
Cedo Bagi, M.D., Ph.D., Senior Research Fellow, Worldwide Comparative Medicine, Global Science & Technology, Pfizer Global R&D
3:40 Refreshment Break in the Exhibit Hall with Poster Viewing
4:40 Interactive Discussion Groups
Concurrent problem-solving discussions on specific topics, to provide a forum for exchanging ideas, voicing opinions and meeting potential collaborators. Discussions will be led by a moderator/s, limited to 15 participants per table, and open to all attendees and exhibitors.
5:40 Welcome Reception in the Exhibit Hall with Poster Viewing
6:45 End of Day
Day 1 | Day 2 | Download Brochure